Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength?

Bio-Techne TECH shares ended the last trading session 10.8% higher at $54.07. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 16.5% loss over the past four weeks.

Bio-Techne scored a strong price increase on investors’ optimism surrounding its impending fiscal 2025 third-quarter financial results, expected to release on May 7 before the opening bell. In the last reported second quarter, both the top and bottom lines surpassed the Zacks Consensus Estimate by 4.1% and 10.5%, respectively.

This maker of medical testing and diagnostic products is expected to post quarterly earnings of $0.52 per share in its upcoming report, which represents a year-over-year change of +8.3%. Revenues are expected to be $316.3 million, up 4.2% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Bio-Techne, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on TECH going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Bio-Techne is part of the Zacks Medical - Biomedical and Genetics industry. NovoCure NVCR, another stock in the same industry, closed the last trading session 10.3% higher at $16.95. NVCR has returned -27.9% in the past month.

NovoCure's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.47. Compared to the company's year-ago EPS, this represents a change of -30.6%. NovoCure currently boasts a Zacks Rank of #4 (Sell).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research